Pharmalot… Pharmalittle… A Little Speech
4 CommentsBy Ed Silverman // October 23rd, 2008 // 5:33 pm
We are rolling up the sidewalks a bit early today because we have a speaking engagement, of all things. The local chapter of the Regulatory Affairs Professional Society has asked us to chat about what we do, why we do it and what we see happening with the great, big pharma world. And so we must now navigate crowded suburban highways - and not get lost. Wish us luck. Meanwhile, here are a few parting gestures…
Bristol-Myers Has ‘Long List’ Of Acquistion Targets (Bloomberg News)
ZymoGenetics Gets $21M To End Patent Suit (The Seattle Times)
Wyeth Defends ‘Unnecessary’ Jobs Cuts (Kildare Nationalist)
riv
Here’s hoping we’ll see the text of your talk Ed.
Ed Silverman
Hi Riv,
Sorry for the belated reply, but your comment got caught in a filter somehow.
Anyway, no, there’s no transcript. I gave a little rundown on the Pharmalot story - the history, how it compares with traditional media, my routine, that sort of thing - and then spent more than an hour fielding a wide variety of questions. It was all very informal. And a nice group of very smart and pleasant people. It was a real pleasure.
Of course, you should feel free to ask me questions any old time.
Best
ed
Lisa
Dear Ed,
Thanks very much for speaking to the RAPS group. I was in the audience, so I appreciate you braving the horrible traffic to get there.
I definitely agreed with you that in the future, pharma will need a stronger presence overseas. Some in the audience seemed to think you meant innovation, but I don’t think that was the point you were trying to make. In my company, a huge emphasis is being placed on the emerging markets. The innovation is still taking place at our major R&D sites, but we are investing heavily in the emerging markets in the areas of clinical trials, regulatory professionals, and sales and marketing. The majority of the profit is still in the US and EU, but the largest area of growth by far is in the Asian and Latin American markets.
As we in the international regulatory community like to point out, 80% of our profit may be from the developed nations, but 80% of our patients at in the rest of world.
Warm regards,
Lisa
Ed Silverman
Hi Lisa,
Thanks for your nice note, and I’m glad the group found the talk useful. The questions were terrific.
And yes, you interpreted my intention correctly. I was simply trying to point out that the balance is shifting, and along with that will come opportunity, but also lots of challenges. Anyway, always happy to kick this around.
All best
ed